Skip to content

The application of indocyanine green fluorescent imaging in laparoscopic inguinal lymphadenectomy for penile cancer

The application of indocyanine green fluorescent imaging in laparoscopic inguinal lymphadenectomy for penile cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044584
Enrollment
Unknown
Registered
2021-03-24
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

penile cancer

Interventions

control group:traditional (robot assisted) laparoscopic inguinal lymphadenectomy
experimental group:indocyanine green fluorescence imaging guided (robot assisted) laparoscopic inguinal lymphadenectomy

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-80 at the time of enrollment; (2) Pathologically diagnosed with penile carcinoma without clinical diagnosis of distant metastasis (except for inguinal lymph node metastasis); (3) For patients requiring inguinal lymph node dissection, indications include but are not limited to: A. poorly differentiated penile carcinoma; B. grade G3 or above penile carcinoma; C. stage T2 or above penile carcinoma; D. tumor with vascular and lymphatic infiltration; (4) Without inguinal and pelvic lymph nodes surgery or radiotherapy , without chemotherapy; (5) The patients or their authorized immediate family members have signed the informed consent for the clinical trial.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of other cancer diagnoses except non-melanoma skin cancer; (2) Patients with chronic pyelonephritis, urolithiasis or uremia; (3) Patients who are not fitted for surgery with severe systemic diseases (including but not limited to the following conditions: severe heart disease and pulmonary insufficiency, uncontrolled diabetes and hypertension, active tuberculosis, etc.) ; (4) Indocyanine green or iodine allergy; (5) In the opinion of the investigator, subjects may not be able to complete the study or comply with the requirements of the study (due to poor management, compliance, etc.).

Design outcomes

Primary

MeasureTime frame
dissected number of lymph nodes;complications;

Secondary

MeasureTime frame
The rates of recurrence and metastasis;Lymph node positive rate ;

Countries

China

Contacts

Public ContactLong Wang

Department of Urology, The Third Xiangya Hospital of Central South University

doctorwanglong@163.com+86 13873151645

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026